δ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it

Abstract

A δ-crystalline form of ivabradine hydrochloride of formula (I): characterised by its powder X-ray diffraction data. Medicinal products containing the same which are useful as bradycardics.

1. A δ-Crystalline form of ivabradine hydrochloride of formula (I): 
       
         
           
           
               
               
           
         
       
       having a powder X-ray diffraction diagram exhibiting peaks at 16.8, 17.9, 19.2, 22.2 and 27.6 deg 2 theta. 
     
     
       2. A δ-Crystalline form of ivabradine hydrochloride of formula (I): 
       
         
           
           
               
               
           
         
       
       having a powder X-ray diffraction diagram exhibiting peaks at 4.1, 8.4 and 10.9 deg 2 theta. 
     
     
       3. A solid pharmaceutical composition comprising as active ingredient the δ-crystalline form of ivabradine hydrochloride of  claim 1 , in combination with one or more pharmaceutically acceptable, inert, non-toxic carriers. 
     
     
       4. A method for treating a condition selected from angina pectoris, myocardial infarct, and heart failure, such method comprising the step of administering to a human, a therapeutically effective amont of a δ-crystalline form of ivabradine hydrochloride of  claim 1 . 
     
     
       5. A solid pharmaceutical composition comprising as active ingredient the δ-crystalline form of ivabradine hydrochloride of  claim 2 , in combination with one or more pharmaceutically acceptable, inert, non-toxic carriers. 
     
     
       6. A method for treating a condition selected from angina pectoris, myocardial infarct, and heart failure, such method comprising the step of administering to a human, a therapeutically effective amont of a δ-crystalline form of ivabradine hydrochloride of  claim 2 .